QUARTERLY REVIEW中文

Hims & Hers Q3 2026: sales up 49%, but margins slide, subscribers dip and profit outlook cut

By · AI-assisted, human-reviewed and edited · · Updated · 13 sources · Fact-checked · 7 min read

Did the story change? Partly

Partly. Sales grew 49% to $890.4 million, the fastest pace this year, helped by branded weight-loss drugs and the Eucalyptus acquisition, within its own guidance, but gross margin fell to 57% from 64% in Q2, and subscribers slipped to 2.788 million from 2.891 million. Hims & Hers cut its 2026 adjusted EBITDA outlook to $257 million to $277 million and lowered the middle of its revenue range. The shares closed down 16.6% at $19.13 on Nov 10, after an 11.8% fall the day before.

What it means

What changed
Hims & Hers cut its 2026 adjusted EBITDA outlook, expects Q4 revenue about flat on Q3, and has fewer subscribers than in June.
What hasn't changed
Revenue is still growing fast, and most US revenue still comes from offerings other than GLP-1 weight-loss drugs.
Next · Jan 14, 2027
A court hearing on Hims & Hers' motion to dismiss the FTC's lawsuit over billing, cancellation and health-data practices.

Closing prices on Nov 10, 2026, from Yahoo Finance and CNBC. The previous close is the official Nov 9 close of $22.94.

Snapshot at the Nov 10, 2026 close

Enterprise value
$5.1B
Price/sales
1.6×
P/E
n/m
Price/FCF
545.4׆
Revenue growth
+30%
Net debt
$655M

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $19.13 (Official close via Yahoo Finance and CNBC); 234.4 million shares (Class A (226,034,799) and Class V (8,377,623) common shares on the cover page of the 10-Q filed Nov 9, 2026). n/m = not meaningful (e.g. negative earnings). † Free cash flow includes $14M of customer prepayments (increase in contract liabilities) in the 12 months to Sep 30, 2026.

Sales were $890.4 million, up 49% from $599.0 million a year earlier and within August’s guidance of $880 million to $900 million; adjusted EBITDA of $82.4 million was within its $75 million to $95 million range. Branded weight-loss drugs and acquisitions, including Australia’s Eucalyptus, drove the growth. But each dollar of sales now brings in less gross profit, fewer people were subscribed at the end of September than at the end of June, and the company lowered what it expects to earn this year.

How the stock reacted

Hims & Hers shares closed down 16.6% at $19.13 on Tuesday, after opening at $22.12 and falling as low as $18.40, while the S&P 500 fell 0.4% (Yahoo Finance and CNBC for Hims & Hers; Yahoo Finance for the index). Revenue was slightly below the $892.9 million analysts expected on average, according to LSEG data cited by Reuters. The shares had already fallen 11.8% on Monday, to $22.94, before the results came out after the close; we found no report that explained that fall. In after-hours trading CNBC quoted the shares at $22.32 at 4:53 p.m. ET, 2.7% below Monday’s close. At Monday’s close the stock was down 29% this year, from $32.47 at the end of 2025 (Yahoo Finance, our calculation).

Did the story change?

In August, Hims & Hers said it expected 2026 revenue of $3.1 billion to $3.3 billion and adjusted EBITDA of $275 million to $325 million, and was “building increased conviction” in its 2030 targets; now it expects $3.13 billion to $3.15 billion and $257 million to $277 million, and neither its results release nor its call mentioned 2030; the finance chief said more on long-term goals would come with its 2027 outlook next quarter. The table compares Q2 with Q3.

Driver Q2 → Q3 2026 Management: before → now Signal
Revenue $753.2M → $890.4M (US $621.8M → $657.1M; rest of world $131.4M → $233.3M) Q3 guided at $880M–$900M → $890.4M; expected US growth “to continue accelerating through the second half” → 21% year on year, up from 16% Better
Gross margin 64% → 57% Expected to “remain below comparative periods in the near term” → fell further, which it ties mainly to weight-loss offerings, growth abroad and acquisitions (10-Qs) Worse
Subscribers 2.891M → 2.788M Up 19% year on year in Q2 → up 13%; the finance chief put the fall down to “measured marketing spend” and warned of another quarter of “headwinds” Worse
Adjusted EBITDA and outlook $60.3M → $82.4M Q3 guided at $75M–$95M → $82.4M; 2026: $275M–$325M → $257M–$277M, which the finance chief tied to price cuts and marketing in the UK and Germany and to deferring some weight-loss membership revenue; Q4 guided at $70M–$90M Worse
Free cash flow –$68.2M → +$26.0M Expected to “resume free cash flow generation in the second half” → positive, after $433.3M from selling receivables; cash and short-term investments of $712.2M at Sep 30 Watch

Sources: Q2 and Q3 results releases and 10-Qs. Comparisons are our calculations from reported figures; adjusted EBITDA and free cash flow are the company’s measures. Q3 adjusted EBITDA newly excludes foreign-currency gains and losses, adding back $4.1 million; without that change it would be $78.3 million (our calculation: $82.388 million minus $4.064 million). Earlier quarters weren’t recast.

Hims & Hers by quarter, Q3 2025 to Q3 2026

Revenue reached $890.4 million in Q3 2026 while gross margin kept falling and subscribers dipped from Q2.

Revenue ($M)05001,000Q3 2025: $599MQ4 2025: $617.8MQ1 2026: $608.1MQ2 2026: $753.2MQ3 2026: $890.4MGross margin (%)50607080Q3 2025: 74%Q4 2025: 72%Q1 2026: 65%Q2 2026: 64%Q3 2026: 57%Subscribers at quarter-end (k)2,4002,6002,8003,000Q3 2025: 2,471 kQ4 2025: 2,511 kQ1 2026: 2,584 kQ2 2026: 2,891 kQ3 2026: 2,788 kQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026Revenue ($M)05001,000Q3 2025: $599MQ4 2025: $617.8MQ1 2026: $608.1MQ2 2026: $753.2MQ3 2026: $890.4MGross margin (%)50607080Q3 2025: 74%Q4 2025: 72%Q1 2026: 65%Q2 2026: 64%Q3 2026: 57%Subscribers at quarter-end (k)2,4002,6002,8003,000Q3 2025: 2,471 kQ4 2025: 2,511 kQ1 2026: 2,584 kQ2 2026: 2,891 kQ3 2026: 2,788 kQ3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Hims & Hers quarterly results releases (SEC 8-Ks). Five quarters; reported gross margins. Excluding Q1 2026's $28.5 million inventory-related restructuring charge gives about 70% for that quarter, against 65% reported (our calculation: ($396.787M + $28.462M) / $608.104M); Q2 and Q3 had no such charge in cost of revenue.
Show the data table
Quarter Revenue ($M) Gross margin (%) Subscribers (thousands)
Q3 2025 599.0 74 2,471
Q4 2025 617.8 72 2,511
Q1 2026 608.1 65 2,584
Q2 2026 753.2 64 2,891
Q3 2026 890.4 57 2,788

What got better

Growth came back at home, as the company said it would. US revenue rose 21% from a year earlier, led by the Hers brand, which made up about 45% of US revenue, on weight loss and dermatology. Most US revenue still came from offerings other than GLP-1 weight-loss drugs, the 10-Q says. Revenue outside the US more than quadrupled to $233.3 million, mainly from acquisitions including Eucalyptus, which it bought in June and which contributed about $135 million, and Hims & Hers raised its 2026 expectation for international revenue to at least $650 million from $600 million (call). Monthly revenue per average subscriber rose 30% to $105; the company’s calculation includes revenue from one-time buyers.

Reported operating cash flow was $65.4 million and free cash flow $26.0 million, after an outflow in Q2, though that included $433.3 million from selling receivables to a bank under a new facility, which brings collections forward. Marketing grew only 7% from a year earlier, to 28% of revenue from 39%, which the chief financial officer said was deliberate, “pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter.” On the call, the company named them: Eli Lilly’s Zepbound and Foundayo through a new agreement, alongside Novo Nordisk’s Wegovy, multi-month subscriptions and, later in November, a first set of peptide treatments.

What needs watching

The cost of growth. Gross profit rose 15% while revenue rose 49%. The company ties most of the margin fall to weight-loss treatments, which ship more often and cost more to fulfil, and to its March switch in the US to branded GLP-1 drugs, with compounded versions only “on a limited scale.” On the call, finance chief Yemi Okupe singled out branded weight-loss products abroad, which “carry lower gross margins,” and said he expects “gross margin declines to start to moderate.” Keonhee Kim, an analyst at research firm Morningstar, told Reuters the branded mix would keep weighing on gross margins in the near term; Reuters didn’t give Morningstar’s rating on the stock. Buying branded drugs takes cash up front: receivables, mostly discounts and rebates owed by drug makers, reached $427.8 million, from $32.1 million at the end of 2025. Its Q4 outlook, $875 million to $895 million in revenue, is about flat on Q3.

Subscribers fell by about 103,000 from June, a 3.6% drop (our calculation). Okupe said they declined “as a result of measured marketing spend” in US weight loss and as acquired brands abroad moved onto the Hims & Hers names, and that holding back in Q4 “may lead to an additional quarter of subscriber count headwinds.” He expects growth to return when marketing picks up in Q1.

The balance sheet has new obligations. It showed $478.6 million of deferred acquisition payments due within a year and a $114.8 million working-capital deficit, which the company mainly attributes to Eucalyptus. Hims & Hers says it can settle most of the Eucalyptus deferred payment in shares, subject to restrictions, which would add to the share count. Convertible notes on the balance sheet were $1.37 billion.

Legal exposure widened. A new securities class action makes claims based on the billing and privacy practices behind the FTC’s lawsuit, which the FTC filed with Utah and Los Angeles County in July. Hims & Hers has moved to dismiss the FTC case, with a hearing set for Jan 14, 2027, and kept its accrual at about $60 million. It says it has “meritorious arguments” against the FTC claims and intends to defend itself vigorously; it does not currently consider a loss on the new securities lawsuit probable.

The board added Andrew Huberman, the Stanford neuroscientist and podcast host, as a non-independent director in November. He will be paid $3.5 million a year for two years for scientific and brand advice, plus up to $1 million a year for short ad videos, and a separate deal of up to three years pays Scicomm Media, a podcast company he co-owns, $5 million a year for advertising. He isn’t on any board committee; the chief executive said on the call that he is advising on standards for the new peptide offering.

Does this change the long-term story?

Our read: the growth case held up this quarter, but the profit case got weaker. Hims & Hers is buying faster growth with branded drugs and acquisitions that earn less per dollar of sales, and its lower outlook shows the trade-off. Whether that pays off depends on margins settling and subscribers growing again after the fourth-quarter expansions; neither is visible yet.

For the full record of filings, dilution and cash, see Hims & Hers: The Long View.

What to watch next

Q4 2026
The "planned expansions" the company paced its marketing for: Eli Lilly's Zepbound and Foundayo through a new agreement, multi-month subscriptions and a first set of peptide treatments. On track would be revenue of $875 million to $895 million with adjusted EBITDA of $70 million to $90 million, as guided.
Jan 14, 2027
The hearing on Hims & Hers' motion to dismiss the FTC lawsuit, filed with Utah and Los Angeles County in July.
Early 2027 (expected)
Fourth-quarter results: whether subscribers grow again and gross margin stops falling, and whether Hims & Hers repeats its 2030 targets.

Quick questions

Why did Hims & Hers' gross margin fall?

The company points mainly to weight-loss treatments, which ship more often and cost more to fulfil, and some of which, since its March switch to branded GLP-1 drugs, cost more to buy. Growth abroad, new offerings and acquisitions added to it. Gross profit still rose 15% from a year earlier, against 49% revenue growth.

Who is Andrew Huberman, and what will Hims & Hers pay him?

He is a Stanford neuroscientist and podcast host. As a non-independent director he gets a $50,000 annual cash retainer and a $250,000 annual equity award, prorated at first. Separately, he gets $3.5 million a year for two years for scientific and brand advice, plus up to $1 million a year for optional short ad videos. Scicomm Media, which he co-owns, gets $5 million a year for podcast advertising for up to three years; the company values his interest at $2.1 million a year. Either side can end that deal for convenience from November 2027.

Updates

  • : Updated to the Nov 10 close: down 16.6% at $19.13.

About Hims & Hers: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.